US2006121091A1PendingUtilityA1

Cellular uptake of bioactive agents

57
Assignee: AESGEN INCPriority: May 17, 1999Filed: Oct 21, 2005Published: Jun 8, 2006
Est. expiryMay 17, 2019(expired)· nominal 20-yr term from priority
Inventors:Robert PetitEdward C. Shinal
A61P 31/12A61P 3/02A61P 29/00A61K 31/198A61P 1/02A23L 33/175A61K 9/0014A61K 47/26A61P 17/02A61P 1/04A61K 9/0095A61K 31/197Y02A50/30
57
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Provided is a composition and a method for increasing cellular uptake of bioactive agents, particularly those compounds termed “small molecules” into the cells of mammalian tissue, such as the epithelial cells of the mucosa.

Claims

exact text as granted — not AI-modified
1 - 26 . (canceled)  
     
     
         27 . A drug formulation comprising: 
 a) L-glutamine; and    b) a solid or semi-solid carrier that can dissolve in an oral cavity.    
     
     
         28 . A drug formulation designed for oral release comprising: 
 a) Le-glutamine; and    b) a solid or semi-solid carrier that dissolves upon oral contact.    
     
     
         29 . The formulation of  claim 27 , wherein the carrier is ingestible or chewable.  
     
     
         30 . The formulation of  claim 27 , provided in a therapeutic dose of L-glutamine.  
     
     
         31 . The formulation of  claim 27 , provided in a dose of at least 3 grains to 4 grams L-glutamine per day.  
     
     
         32 . The formulation of  claim 27 , farther comprising a flavoring or an antiseptic.  
     
     
         33 . The formulation of  claim 27 , wherein the carrier comprises water.  
     
     
         34 . The formulation of  claim 27 , wherein the carrier is a gel.  
     
     
         35 . The formulation of  claim 27 , wherein the carrier comprises water and a gelling agent.  
     
     
         36 . The formulation of  claim 27 , provided as a lozenge, a biodegradable insert, a lollipop, or a popsicle.  
     
     
         37 . The formulation of  claim 27 , provided as a lozenge, a lollipop, or a popsicle.  
     
     
         38 . The formulation of  claim 27 , provided as a biodegradable insert.  
     
     
         39 . The formulation of  claim 27 , wherein the carrier can dissolve in response to an aqueous environment.  
     
     
         40 . The formulation of  claim 27 , wherein the carrier can dissolve in an in vivo environment.  
     
     
         41 . The formulation of  claim 27 , wherein the carrier can dissolve in response to an in vivo aqueous environment.  
     
     
         42 . The formulation of  claim 27 , wherein the carrier can dissolve in an oral cavity.  
     
     
         43 . The formulation of  claim 27 , provided as a popsicle comprising a flavoring.  
     
     
         44 . A method of treating mucositis comprising administering to a subject in need thereof a drug formulation for uptake into the oral cavity comprising: 
 a) L-glutamine; and    b) a solid or semisolid carrier that is dissolved by surrounding fluids in a mouth.    
     
     
         45 . A method of treating oral inflammation comprising administering to a subject in need thereof a drug formulation for uptake into the oral cavity comprising: 
 a) L-glutamine; and    b) a solid or semisolid carrier that is dissolved by surrounding fluids in a mouth.    
     
     
         46 . The method of  claim 44 , wherein the carrier is ingestible or chewable.  
     
     
         47 . The method of  claim 44 , wherein the formulation farther comprises a flavoring or an antiseptic.  
     
     
         48 . The method of  claim 44 , wherein the carrier comprises water.  
     
     
         49 . The method of  claim 44 , wherein the carrier is a gel.  
     
     
         50 . The method of  claim 44 , wherein the form comprises a gelling agent or a mixture of water and a gelling agent.  
     
     
         51 . The method of  claim 44 , wherein the formulation is provided as a lozenge, a biodegradable if a lollipop or a popsicle.  
     
     
         52 . The method of  claim 44 , wherein the formulation is provided as a lozenge, a lollipop or a popsicle.  
     
     
         53 . The method of  claim 44 , wherein the formulation is provided as a biodegradable insert.  
     
     
         54 . The method of  claim 44 , wherein the carrier can dissolve in response to an aqueous environment.  
     
     
         55 . The method of  claim 44 , wherein the carrier can dissolve in response to an in vivo aqueous environment.  
     
     
         56 . The method of  claim 44 , wherein the carrier can dissolve in an oral cavity.  
     
     
         57 . The method of  claim 44 , wherein the formulation is provided as a popsicle comprising a flavoring.  
     
     
         58 . The method of  claim 44 , wherein the formulation is frozen.  
     
     
         59 . The method of  claim 44 , wherein the oral inflammation is chemotherapy-induced or radiation-induced.  
     
     
         60 . A storage stable drug formulation comprising L-glutamine frozen in a flavored carrier.  
     
     
         61 . The formulation of  claim 60 , provided in a therapeutic dose of L-glutamine.  
     
     
         62 . The formulation of  claim 60 , provided in a dose of at least 3 grams to 4 grams L-glutamine per day.  
     
     
         63 . A kit comprising: 
 a) L-glutamine; and    b) a flavoring.    
     
     
         64 . The kit of  claim 63 , further comprising: 
 c) an ingestible or chewable carrier.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.